Cell-mediated immunotherapy for hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Most of the time, these tumors are diagnosed at late stages. Because no effective treatments exist for patients with advanced stage HCC, there is an urgent need for novel, effective treatments. Cancer cells originate as a consequence of abnormal expression of oncogenes or loss of tumor suppressor genes. Often, neoplastic transformation results in a hyper-mutated cellular genome, which in turn produces neo-antigens from mutated genes. These tumor-specific or tumor-associated antigens can be recognized by antigen-presenting cells and trigger T-lymphocytes to elicit anticancer immunity. Immune responses to cancers are often rendered ineffective by tumor immune-editing and immune-suppressive mechanisms. Yet, therapeutic strategies to stimulate anti-cancer immunity have had remarkable success in several solid and hematological malignancies. Among the various strategies for cancer immunotherapy, cell-mediated immunotherapy holds considerable promise to overcome anergy and systemic immune suppression. This brief review will focus on cell-mediated immunotherapy for HCC.

Keywords

Hepatocellular carcinoma / dendritic cell / immunotherapy

References

[1] Ferenci P,Labrecque D,Sherman M,Heathcote J,Kew M,Zheng SS,Hamid SS,Fleig W,Thomson A,Malfertheiner P,Carillo FJ,Le Mair A.Hepatocellular carcinoma (HCC): a global perspective..J Clin Gastroenterol2010;44:239-45

[2] Mazzaferro V,Doci R,Pulvirenti A,Montalto F,Morabito A.Liver transplantation for the treatment of small hepatocellularcarcinomas in patients with cirrhosis..N Engl J Med1996;334:693-9

[3] Yao FY,Bass NM,Bacchetti P,Ascher NL.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival..Hepatology2001;33:1394-403

[4] Lee WC,Cheng CH,Chou HS,Soong RS,Yu MC.Outcomes of liver resection for hepatocellular carcinoma in liver transplantation era..Eur J Surg Oncol2015;41:1144-52

[5] Meza-Junco J,Liu DM,Bain VG,Owen R.Locoregional radiological treatment for hepatocellular carcinoma; which, when and how?.Cancer Treat Rev2012;38:54-62

[6] Ray CEJr,Geschwind JF.The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011..J Vasc Interv Radiol2011;22:1693-6 PMCID:PMC4332810

[7] Raoul JL,Forner A,Piscaglia F,Lencioni R.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization..Cancer Treat Rev2011;37:212-20

[8] Cheng AL,Chen Z,Qin S,Luo R,Ye S,Xu J,Liang H,Wang J,Pan H,Zou J,Guan Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial..Lancet Oncol2009;10:25-34

[9] Kudo M.Molecular targeted therapy for hepatocellular carcinoma: bench to bedside..Dig Dis2011;29:273-7

[10] Ling TC,Bush DA,Yang GY.Proton therapy for hepatocellular carcinoma..Chin J Cancer Res2012;24:367-73

[11] Ishikawa T.Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma..World J Gastroenterol2008;14:2797-801 PMCID:PMC2710718

[12] Forner A,de Lope CR.Current strategy for staging and treatment: the BCLC update and future prospects..Semin Liver Dis2010;30:61-74

[13] Kurkjian C,Murgo AJ.DNA methylation: its role in cancer development and therapy..Curr Probl Cancer2008;32:187-235 PMCID:PMC2588419

[14] Palucka K.Dendritic-cell-based therapeutic cancer vaccines..Immunity2013;39:38-48 PMCID:PMC3788678

[15] Lotze MT.Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer..Ann Surg1997;226:1-5 PMCID:PMC1190900

[16] Gabrilovich DI,Carbone DP.Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts..Cell Immunol1996;170:101-10

[17] Tarte K.Dendritic cell-based vaccine: a promising approach for cancer immunotherapy..Leukemia1999;13:653-63

[18] Grabbe S,Schwarz T.Dendritic cells as initiators of tumor immune responses: a possible of tumor immune strategy for tumor immunotherapy..Immunol Today1995;16:117-21

[19] Hsu FJ,Fagnoni F,Czerwinski D,Engleman EG.Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells..Nat Med1996;2:52-8

[20] Nestle FO,Gilliet M,Grabbe S,Burg G.Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells..Nat Med1998;4:328-32

[21] Höltl L,Papesh C,Bartsch G.CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer..Lancet1998;352:1358

[22] Di Lorenzo G,Kantoff PW.Immunotherapy for the treatment of prostate cancer..Nat Rev Clin Oncol2011;8:551-61

[23] Bauer C,Saraj S,Bauernfeind F,Junkmann J,Kiefl R,Emmerich B,Mussack T,Rüttinger D,Jauch KW,Eigler A.Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study..Cancer Immunol Immunother2011;60:1097-107

[24] Tarte K.Dendritic cell-based vaccine: a promising approach for cancer immunotherapy..Leukemia1999;13:653-63

[25] Lee WC,Hung CF,Lia CR.Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial..J Immunither2005;28:496-504

[26] Wang HY.Regulatory T cells and cancer..Curr Opin Immunol2007;19:217-23

[27] Lee WC,Chou HS,Hsu PY,Wang CC.The impact of CD4+CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma..Surgery2012;151:213-22

[28] Vignali DA,Workman CJ.How regulatory T cells work..Nat Rev Immunol2008;8:523-32 PMCID:PMC2665249

[29] Huang CH,Pai MH,Yeh SL.Dietary omega-6/omega-3 polyunsaturated fatty acid ratios affect the homeostasis of Th/Treg cells in mice with dextran sulfate sodium-induced colitis..JPEN J Parenter Enteral Nutr2017;41:647-56

[30] Chen X,Lin X,Zhou T.CD4+CD25+ regulatory T cells in tumor immunity..Int Immunopharmacol2016;34:244-9

[31] Kindlund B,Yakkala C,Janzon A,Hermansson M,Winqvist O.CD4+ regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF-beta..Gastric Cancer2017;20:116-25

[32] Shen LS,Shen DF,Dong P,Xue J,Ge HL.CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression..Clin Immunol2009;131:109-18

[33] Xu T,Wang G.CD4 + CD25high regulatory T cell numbers and FOXP3 mRNA expression in patients with advanced esophageal cancer before and after chemotherapy..Cell Biochem Biophys2011;61:389-92

[34] Kim S,Lim W,Cho MS,Moon BI.Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer..J Breast Cancer2014;17:8-17 PMCID:PMC3988347

[35] O'Callaghan DS,Gately K,Delaney D,Kay E,Gallagher WM.Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer..Eur Respir J2015;46:1762-72

[36] Lee WC,Chou HS,Hsu PY,Wang CC.The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma..Surgery2012;151:213-22

[37] Gabrilovich DI,Chen SH,Ochoa A,Schreiber H.The terminology issue for myeloid-derived suppressor cells..Cancer Res2007;67:425; author reply 426 PMCID:PMC1941787

[38] Movahedi K,Van den Bossche J,Gysemans C,De Baetselier P.Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity..Blood2008;111:4233-44

[39] Peranzoni E,Marigo I,Zanovello P,Bronte V.Myeloid-derived suppressor cell heterogeneity and subset definition..Curr Opin Immunol2010;22:238-44

[40] Ueha S,Matsushima K.Myeloid cell population dynamics in healthy and tumor-bearing mice..Int Immunopharmacol2011;11:783-8

[41] Ko JS,Ireland J,Li G,Rini B,Cohen PA.Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained..Cancer Res2010;70:3526-36 PMCID:PMC3426924

[42] Ozao-Choy J,Kao J,Meseck M,Schwartz M,Pan PY.The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies..Cancer Res2009;69:2514-22 PMCID:PMC4370269

[43] Daurkin I,Vieweg J.Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine..Cancer Immunol Immunother2010;59:697-706

[44] Gabrilovich DI.Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited..Lancet Oncol2007;8:2-3

[45] Kusmartsev S,Yu B,Sotomayor E,Gabrilovich D.All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination..Cancer Res2003;63:4441-9

[46] De Santo C,Marigo I,Bolla M,Melani C,Colombo MP,Musiani P,Bronte V.Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination..Proc Natl Acad Sci U S A2005;102:4185-90 PMCID:PMC554823

[47] Suzuki E,Jassar AS,Albelda SM.Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity..Clin Cancer Res2005;11:6713-21

[48] Mirza N,Fricke I,Neuger AM,Lush RM,Gabrilovich DI.All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients..Cancer Res2006;66:9299-307 PMCID:PMC1586106

[49] Iwashita Y,Goto S,Kai S,Chen CL,Kitano S.A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer..Cancer Immunol Immunother2003;52:155-61

[50] Palmer DH,Mirza N,Ahmed F,Steven NM,Young LS.A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma..Hepatology2009;49:124-32

[51] Qiu Y,Yun MM,Zhang RM,Ou-Yang XH.Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells..World J Gastroenterol2011;17:5260-6 PMCID:PMC3247689

[52] Nakamoto Y,Tsuji H,Kitahara M,Yamashita T,Mukaida N,Matsui O.Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety..Clin Exp Immunol2007;147:296-305 PMCID:PMC1810477

[53] Sangro B,de la Mata M,Garralda E,Riezu-Boj JI,Alfaro C,Lasarte JJ,Melero I.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C..J Hepatol2013;59:81-8

[54] El-Khoueiry AB,Yau T,Kudo M,Kim TY,Trojan J,Meyer T,Yeo W,Anderson J,Lang L,Tang H,Melero I.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502

[55] Brenner MK.Adoptive T cell therapy of cancer..Curr Opin Immunol2010;22:251-7 PMCID:PMC3093371

[56] Takayama T,Makuuchi M,Kosuge T,Shimada K,Hirohashi S,Kakizoe T.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial..Lancet2000;356:802-7

[57] Jiang SS,Zhang YJ,Zhou ZG,Pan QZ,Liu Q,Zhao JJ,Chen MS,Li Q.A phase I clinical trial utilizing autologous tumor-infiltratinglymphocytes in patients with primary hepatocellular carcinoma..Oncotarget2015;6:41339-49 PMCID:PMC4747409

[58] Shi M,Tang ZR,Wang HF,Fan ZP,Wang FS.Autologous cytokine-induced killer cell therapy in clinical trial phaseI is safe in patients with primary hepatocellular carcinoma..World J Gastroenterol2004;10:1146-51 PMCID:PMC4656350

[59] Hao M,Chen Q,Chen QZ.Efficacy of transcatheter arterial chemoembolizationcombined with cytokineinduced killer cell therapy onhepatocellular carcinoma: a comparative study..Chin J Cancer2010;29:172-7

[60] Su Y,Ma Y,Rao W,Kou C.The efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cell therapy in combination with TACE-predominant minimally-invasive treatment for hepatocellular carcinoma: a meta-analysis..Clin Lab2016;62:599-608

[61] Hong Y.Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma..World J Hepatol2015;7:1581-5 PMCID:PMC4462696

[62] Sun Z,Xia J,Kokudo N.Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials..Biosci Trends2016;10:85-91

[63] Aref AM,Ge L,Dacosta-Iyer M,Ouyang Y,Jadus MR.HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma..Onco Targets Ther2014;7:1061-70 PMCID:PMC4063820

[64] Zhu Z,Liu Y,Li R,Gu B,Zhang S.Screening and identification of the tumor-associated antigen CK10, a novel potential liver cancer marker..FEBS Open Bio2017;7:627-35 PMCID:PMC5407893